Home | Contact Us | FAQ | Search & Site Map | Link to Us
Sign In | Join | Other 45 Sites in Network
Home
Discussion Groups
General
GeneralCardiologyVisionDentistryPharmacyLaboratoryNutritionAlternative
Diseases and Disorders
AIDSAlzheimer'sArthritisAsthmaCancerBreast CancerDiabetesEpilepsyGlaucomaHepatitisHerpesLupusProstate BPHProstate CancerProstatitisSinusitisTinnitus

Medical Forum / Diseases and Disorders / Hepatitis / June 2009

Tip: Looking for answers? Try searching our database.

Liver Disease

Thread view: 
Enable EMail Alerts  Start New Thread
Thread rating: 
ironjustice - 01 Jun 2009 14:46 GMT
Liver disease 'shrunk' by blood-pressure drug
June 1st, 2009 A blood-pressure medicine has been shown to reverse the
effects of early-stage liver failure in some patients.

Newcastle University researchers analysed a small clinical trial of
losartan, a drug normally prescribed for hypertension, on 14 patients
in Spain, who had Hepatitis C.

The illness was at an advanced stage causing fibrosis - scarring in
the liver - which would usually have progressed to liver failure.

Half of the patients in the trial saw the scars in their liver shrink
allowing the organ to repair itself.

Professor Derek Mann from Newcastle University said: "At the moment we
have no proven effective way of treating people with chronic liver
disease other than transplantation. This early stage trial has shown
that we can shrink liver scarring in some patients and shows promise
for a treatment that could make a huge difference to the lives of
thousands of people."

The team whose work is published today in Gastroenterology, say this
early stage trial is promising and they now want to carry out several
much larger studies initially involving patients with liver disease
caused by obesity and then later alcohol, hereditary and autoimmune
diseases.

Mechanism

Liver damage, known as fibrosis, is caused by the unwanted
accumulation of excess fibrous connective tissue which is produced and
maintained by a specialised cell, the liver myofibroblast.

In chronic liver disease a signalling pathway is created that
instructs the liver myofibroblast to stay alive and proliferate. It is
this pathway that then causes scar tissue to accumulate, creating the
liver damage.

Work carried out in rat and mouse models allowed the researchers to
study what was happening inside the liver when losartan, an
angiotensin II receptor antagonist drug, was present.

Researchers believe that the drug blocks the signalling pathway so
that the liver myofibroblasts die, removing the source of scar tissue.
As the scar tissue breaks up, the damaged area of the liver is
repaired by the body.

In this research, funded by the Medical Research Council and the
British Liver Trust, the Newcastle University researchers discovered a
biological marker, NF-kB, was crucial for the activities of scar-
forming cells.

Tests on their livers revealed that, before treatment with losartan,
half of the patients had a high level of the biomarker NF-kB. After
treatment, the level fell indicating that losartan is able to switch
off NF-kB with the result that scars are no longer produced or
maintained, but instead shrink.

Professor Mann said: "By measuring the amount of active NF-kB in the
liver from a biopsy sample, we may be able to tell which patients will
benefit from treatment with losartan or similar drugs such as ACE
inhibitors. This may prove to be a new treatment for up to half of all
liver patients."

More information: Angiotensin II activates IkB kinase phosphorylation
of Re1A at Ser536 to promote myofibroblast survival and liver
fibrosis, Gastroenterology, June 1, 2009

Source: Newcastle University
--------------

"Losartan reduces hematocrit"

More .. pharmacalogical .. bloodletting ..

Coincidence of course .. that it is used for .. diabetes which has
been recently found to .. have .. increased red blood cell
production ..

Losartan reduces hematocrit in patients with chronic obstructive
pulmonary disease and secondary erythrocytosis.
Ann Intern Med. 2001 Mar 6;134(5):426-7.
Vlahakos DV, Marathias KP, Kosmas EN.

Publication Types:
Comment
Letter

PMID: 11242510

-----------------

Who loves ya.
Tom

Jesus Was A Vegetarian!
http://tinyurl.com/2r2nkh

Man Is A Herbivore!
http://tinyurl.com/4rq595

DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk
Rusty the Spamming Fuckwadd - 01 Jun 2009 16:16 GMT
Spamming Retard
ironjustice - 01 Jun 2009 17:44 GMT
On Jun 1, 8:16 am, Rusty the Spamming Fuckwadd
<flakey...@earthlink.net> wrote::snip <<

What did I tell you about little atheist .. btches .. ?

No atheist btches on my threads ..

Take your predatorial atheist nature .. elsewhere .. looooon ..

DOOOOO it .. looooon ..

DOOOOO .. it ..

You seem to find .. stay off my threads .. hard to understand  ..
shteater ..

That would be because you are a .. shteating .. **freak** ..

http://www.traditionalvalues.org/homosexual_movement_and_pedophilia/

http://www.talk2action.org/story/2006/10/3/21245/3789

------------------

Liver disease 'shrunk' by blood-pressure drug
June 1st, 2009 A blood-pressure medicine has been shown to reverse
the
effects of early-stage liver failure in some patients.

Newcastle University researchers analysed a small clinical trial of
losartan, a drug normally prescribed for hypertension, on 14 patients
in Spain, who had Hepatitis C.

The illness was at an advanced stage causing fibrosis - scarring in
the liver - which would usually have progressed to liver failure.

Half of the patients in the trial saw the scars in their liver shrink
allowing the organ to repair itself.

Professor Derek Mann from Newcastle University said: "At the moment
we
have no proven effective way of treating people with chronic liver
disease other than transplantation. This early stage trial has shown
that we can shrink liver scarring in some patients and shows promise
for a treatment that could make a huge difference to the lives of
thousands of people."

The team whose work is published today in Gastroenterology, say this
early stage trial is promising and they now want to carry out several
much larger studies initially involving patients with liver disease
caused by obesity and then later alcohol, hereditary and autoimmune
diseases.

Mechanism

Liver damage, known as fibrosis, is caused by the unwanted
accumulation of excess fibrous connective tissue which is produced
and
maintained by a specialised cell, the liver myofibroblast.

In chronic liver disease a signalling pathway is created that
instructs the liver myofibroblast to stay alive and proliferate. It
is
this pathway that then causes scar tissue to accumulate, creating the
liver damage.

Work carried out in rat and mouse models allowed the researchers to
study what was happening inside the liver when losartan, an
angiotensin II receptor antagonist drug, was present.

Researchers believe that the drug blocks the signalling pathway so
that the liver myofibroblasts die, removing the source of scar
tissue.
As the scar tissue breaks up, the damaged area of the liver is
repaired by the body.

In this research, funded by the Medical Research Council and the
British Liver Trust, the Newcastle University researchers discovered
a
biological marker, NF-kB, was crucial for the activities of scar-
forming cells.

Tests on their livers revealed that, before treatment with losartan,
half of the patients had a high level of the biomarker NF-kB. After
treatment, the level fell indicating that losartan is able to switch
off NF-kB with the result that scars are no longer produced or
maintained, but instead shrink.

Professor Mann said: "By measuring the amount of active NF-kB in the
liver from a biopsy sample, we may be able to tell which patients
will
benefit from treatment with losartan or similar drugs such as ACE
inhibitors. This may prove to be a new treatment for up to half of
all
liver patients."

More information: Angiotensin II activates IkB kinase phosphorylation
of Re1A at Ser536 to promote myofibroblast survival and liver
fibrosis, Gastroenterology, June 1, 2009

Source: Newcastle University
--------------

"Losartan reduces hematocrit"

More .. pharmacalogical .. bloodletting ..

Coincidence of course .. that it is used for .. diabetes which has
been recently found to .. have .. increased red blood cell
production ..

Losartan reduces hematocrit in patients with chronic obstructive
pulmonary disease and secondary erythrocytosis.
Ann Intern Med. 2001 Mar 6;134(5):426-7.
Vlahakos DV, Marathias KP, Kosmas EN.

Publication Types:
Comment
Letter

PMID: 11242510

-----------------

Who loves ya.
Tom

Jesus Was A Vegetarian!
http://tinyurl.com/2r2nkh

Man Is A Herbivore!
http://tinyurl.com/4rq595

DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk
Rusty the Spamming Dickhead - 01 Jun 2009 20:22 GMT
Spamming Dickwadd
ironjustice - 02 Jun 2009 03:07 GMT
On Jun 1, 12:22 pm, Rusty the Spamming Dickhead
<flakey...@earthlink.net> wrote:snip <<

You shteating atheist ..

You homosexual .. atheist .. shteaters .. with .. severe bisexual
conflict and confusion .. have been TOLD .. many times ..
stay OFF **my** threads ..

What did I tell you about little atheist .. btches .. ?

No atheist btches on my threads ..

Take your predatorial atheist shteating nature .. elsewhere ..
looooon ..

DOOOOO it .. looooon ..

DOOOOO .. it ..

You seem to find .. stay off my threads .. hard to understand  ..
shteater ..

That would be because you are a .. shteating .. **freak** ..

http://www.traditionalvalues.org/homosexual_movement_and_pedophilia/

http://www.talk2action.org/story/2006/10/3/21245/3789

http//tinyurl.com/dxxfr5

Severe bisexual conflict and confusion was discovered to be the
cause of schizophrenia over fifty years ago by Dr. Edward J.
Kempf and others

-------------------

Liver disease 'shrunk' by blood-pressure drug
June 1st, 2009 A blood-pressure medicine has been shown to reverse
the
effects of early-stage liver failure in some patients.

Newcastle University researchers analysed a small clinical trial of
losartan, a drug normally prescribed for hypertension, on 14 patients
in Spain, who had Hepatitis C.

The illness was at an advanced stage causing fibrosis - scarring in
the liver - which would usually have progressed to liver failure.

Half of the patients in the trial saw the scars in their liver shrink
allowing the organ to repair itself.

Professor Derek Mann from Newcastle University said: "At the moment
we
have no proven effective way of treating people with chronic liver
disease other than transplantation. This early stage trial has shown
that we can shrink liver scarring in some patients and shows promise
for a treatment that could make a huge difference to the lives of
thousands of people."

The team whose work is published today in Gastroenterology, say this
early stage trial is promising and they now want to carry out several
much larger studies initially involving patients with liver disease
caused by obesity and then later alcohol, hereditary and autoimmune
diseases.

Mechanism

Liver damage, known as fibrosis, is caused by the unwanted
accumulation of excess fibrous connective tissue which is produced
and
maintained by a specialised cell, the liver myofibroblast.

In chronic liver disease a signalling pathway is created that
instructs the liver myofibroblast to stay alive and proliferate. It
is
this pathway that then causes scar tissue to accumulate, creating the
liver damage.

Work carried out in rat and mouse models allowed the researchers to
study what was happening inside the liver when losartan, an
angiotensin II receptor antagonist drug, was present.

Researchers believe that the drug blocks the signalling pathway so
that the liver myofibroblasts die, removing the source of scar
tissue.
As the scar tissue breaks up, the damaged area of the liver is
repaired by the body.

In this research, funded by the Medical Research Council and the
British Liver Trust, the Newcastle University researchers discovered
a
biological marker, NF-kB, was crucial for the activities of scar-
forming cells.

Tests on their livers revealed that, before treatment with losartan,
half of the patients had a high level of the biomarker NF-kB. After
treatment, the level fell indicating that losartan is able to switch
off NF-kB with the result that scars are no longer produced or
maintained, but instead shrink.

Professor Mann said: "By measuring the amount of active NF-kB in the
liver from a biopsy sample, we may be able to tell which patients
will
benefit from treatment with losartan or similar drugs such as ACE
inhibitors. This may prove to be a new treatment for up to half of
all
liver patients."

More information: Angiotensin II activates IkB kinase phosphorylation
of Re1A at Ser536 to promote myofibroblast survival and liver
fibrosis, Gastroenterology, June 1, 2009

Source: Newcastle University
--------------

"Losartan reduces hematocrit"

More .. pharmacalogical .. bloodletting ..

Coincidence of course .. that it is used for .. diabetes which has
been recently found to .. have .. increased red blood cell
production ..

Losartan reduces hematocrit in patients with chronic obstructive
pulmonary disease and secondary erythrocytosis.
Ann Intern Med. 2001 Mar 6;134(5):426-7.
Vlahakos DV, Marathias KP, Kosmas EN.

Publication Types:
Comment
Letter

PMID: 11242510

-----------------

Who loves ya.
Tom

Jesus Was A Vegetarian!
http://tinyurl.com/2r2nkh

Man Is A Herbivore!
http://tinyurl.com/4rq595

DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk
Thip - 02 Jun 2009 23:16 GMT
Interesting info.  I did a little extra investigating and it might hold some
promise for folks like me.
 
Sign In
Join
My Latest Posts
My Monitored Threads
My Blog
My Photo Gallery
My Profile
My Homepage

Start New Thread
Enable EMail Alerts
Rate this Thread



©2009 Advenet LLC   Privacy Policy - Terms of Use
This website includes both content owned or controlled by Advenet as well as content owned or controlled by third parties.